Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 92, Issue 5, Pages 548-550Publisher
WILEY
DOI: 10.1038/clpt.2012.99
Keywords
-
Categories
Funding
- NCI NIH HHS [K23CA124802, K23 CA124802] Funding Source: Medline
- NIGMS NIH HHS [T32GM007019, T32 GM007019] Funding Source: Medline
Ask authors/readers for more resources
Simulations based on disease-progression models and phase II trial results can predict phase II results and have the potential to improve oncology drug development by informing end-of-phase II decisions (EOP2Ds). Many barriers impede effective use of modeling and simulation (M&S) for EOP2Ds in oncology: concerns about model validity, lack of access to M&S results and patient-level data, limited awareness of M&S among academic oncologists, and inexperience fitting M&S into the drug development timeline.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available